PMCB · Pharmacyte Biotech, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $93.1K | $141.1K | $95.2K | $97.5K | $118.2K | $96.0K | $82.0K | $126.7K | $104.5K | - |
| SG&A | $2.02M | $1.23M | $753.1K | $117.6K | $241.2K | $134.8K | $272.5K | $251.9K | $1.36M | - |
| Total Operating Expenses | $2.12M | $1.38M | $848.3K | $1.11M | $960.3K | $1.27M | $1.41M | $1.87M | $2.08M | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($2.12M) | ($1.38M) | ($848.3K) | ($1.11M) | ($960.3K) | ($1.27M) | ($1.41M) | ($1.87M) | ($2.08M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | $746.9K | ($7.42M) | ($8.36M) | ($1.47M) | ($3.05M) | $23.42M | $2.79M | ($619.5K) | ($3.18M) | - |
| EPS - Basic | ($0.17) | ($1.24) | ($1.23) | ($0.39) | ($0.44) | $1.90 | ($0.26) | ($0.65) | ($0.28) | - |
| EPS - Diluted | ($0.17) | ($1.24) | ($1.23) | ($0.39) | ($0.44) | $1.90 | ($0.26) | ($0.65) | ($0.28) | - |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.17M | $15.41M | $13.18M | $15.17M | $16.38M | $32.64M | $50.18M | $61.21M | $74.66M | $68.04M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.20M | $1.02M | $465.2K | $399.2K | $484.9K | $554.0K | $389.4K | $484.2K | $718.1K | $128.3K |
| Current Assets | $20.70M | $23.02M | $19.11M | $22.38M | $16.96M | $32.88M | $50.44M | $61.51M | $74.75M | $68.15M |
| Total Assets | $55.87M | $55.98M | $45.11M | $55.17M | $43.83M | $70.19M | $59.90M | $71.36M | $79.88M | $73.28M |
| Current Liabilities | $1.68M | $1.58M | $1.06M | $2.91M | $1.19M | $7.47M | $7.42M | $7.54M | $1.52M | $586.6K |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $16.47M | $19.42M | $1.52M | $3.28M | $3.58M | $17.15M | $20.39M | $22.47M | $20.40M | $586.6K |
| Stockholders' Equity | $38.11M | $35.24M | $43.59M | $51.89M | $40.25M | $47.71M | $27.65M | $31.37M | $42.73M | $72.69M |
| Retained Earnings | ($100.00M) | ($100.75M) | ($93.33M) | ($84.97M) | ($96.72M) | ($92.20M) | ($115.63M) | ($116.97M) | ($119.46M) | ($115.96M) |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($1.99M) | - | - | ($373.3K) | - | - | $343.0K | - |
| Investing Cash Flow | - | - | $0 | - | - | ($7.00M) | - | - | $0 | - |
| Financing Cash Flow | - | - | $0 | - | - | ($10.17M) | - | - | $6.28M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | 1.3% | -13.3% | -18.5% | -2.7% | -6.9% | 33.4% | 4.7% | -0.9% | -4.0% | - |
| Return on equity | 2.0% | -21.1% | -19.2% | -2.8% | -7.6% | 49.1% | 10.1% | -2.0% | -7.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 12.33 | 14.60 | 18.01 | 7.68 | 14.20 | 4.40 | 6.80 | 8.16 | 49.24 | 116.18 |
| Quick ratio | 12.33 | 14.60 | 18.01 | 7.68 | 14.20 | 4.40 | 6.80 | 8.16 | 49.24 | 116.18 |
| Cash ratio | 12.02 | 9.77 | 12.42 | 5.21 | 13.72 | 4.37 | 6.76 | 8.12 | 49.18 | 115.99 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.47 | 1.59 | 1.03 | 1.06 | 1.09 | 1.47 | 2.17 | 2.27 | 1.87 | 1.01 |
| Liabilities / Assets | 0.29 | 0.35 | 0.03 | 0.06 | 0.08 | 0.24 | 0.34 | 0.31 | 0.26 | 0.01 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | 1.0x | - | - | - | - |
| P / B | 0.2x | 0.2x | 0.2x | 0.2x | 0.3x | 0.3x | 0.7x | 0.6x | 0.8x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -120.6% | -24.4% | 33.1% | 21.5% | 48.6% | 38.9% | - | -20.3% | -23.5% | - |
| Net income growth (YoY) | - | -404.8% | - | - | -391.5% | - | - | 18.9% | -106.0% | - |
| EPS growth (YoY) | 61.4% | -217.9% | - | -50.0% | 32.3% | - | - | -1525.0% | -300.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -5.3% | -32.1% | -8.6% | 87.7% | 28.3% | 11.6% | -62.0% | -59.3% | -50.5% | -10.3% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing PharmaCyte Biotech against the 5 most active filers in the same SIC group.